Adimmune Inks Flu Vaccine Deal with Daiichi Sankyo to Crack Japan Market

Taiwan-based Adimmune Corp. (“Adimmune”) signed a cooperative pack with a Japan-based pharmaceutical company, Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) on September 8, 2015.  Mr. CHAN Chi-Shean, chairman of Adimmune said that this tie-up sets a new milestone for the two companies’ cooperation and their interchange of experiences in the pharmaceutical sector is expected to bring synergy effects.

According to the pack, Adimmune shall produce flu vaccine solutions sufficient for four million doses annually over the first stage of five years, and Daiichi Sankyo should use the solutions to produce vaccine for the demand from Japan market.

Cooperation with Daiichi Sankyo marks another significant cooperation project of Adimmune following its acquiring certification from the EU Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) for supply of flu vaccine solutions to the European market.  Collaboration between the two companies is believed to facilitate integration of advanced R&D, manufacturing, and quality control of Taiwan and Japan so as to establish a high-quality upstream and downstream flu vaccine supply chain and to tap into the international market.  (September 2015)
/CCS